MFH
MCID: MLG065
MIFTS: 44

Malignant Fibroxanthoma (MFH)

Categories: Cancer diseases

Aliases & Classifications for Malignant Fibroxanthoma

MalaCards integrated aliases for Malignant Fibroxanthoma:

Name: Malignant Fibroxanthoma 12 15
Malignant Fibrous Histiocytoma 74 54 15 71
Histiocytoma, Fibrous, Malignant 39
Fibrous Histiocytoma, Malignant 12
Histiocytoma, Malignant Fibrous 43
Fibroxanthosarcoma 12
Mfh 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1907
MeSH 43 D051677
NCIt 49 C4247
SNOMED-CT 67 34360000
UMLS 71 C0334463

Summaries for Malignant Fibroxanthoma

MalaCards based summary : Malignant Fibroxanthoma, also known as malignant fibrous histiocytoma, is related to secretory meningioma and fibrous histiocytoma. An important gene associated with Malignant Fibroxanthoma is SERPINA3 (Serpin Family A Member 3), and among its related pathways/superpathways are Innate Immune System and Striated Muscle Contraction. The drugs Mechlorethamine and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and lung, and related phenotypes are Decreased cell migration and Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance

Wikipedia : 74 Undifferentiated pleomorphic sarcoma, previously malignant fibrous histiocytoma, is a type of cancer,... more...

Related Diseases for Malignant Fibroxanthoma

Diseases related to Malignant Fibroxanthoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 609)
# Related Disease Score Top Affiliating Genes
1 secretory meningioma 31.4 VIM SERPINA3 MUC1
2 fibrous histiocytoma 31.4 VIM SERPINA3 F13A1 DES CD68 ALK
3 malignant giant cell tumor 31.3 CD68 ACTC1
4 retroperitoneal sarcoma 31.3 MYOG MDM2 CDK4
5 fasciitis 31.2 VIM DES ACTC1
6 spindle cell carcinoma 31.1 VIM MUC1 DES ACTC1
7 xanthogranulomatous pyelonephritis 31.1 SERPINA3 CD68
8 pleomorphic rhabdomyosarcoma 31.0 MYOG MYOD1 ACTC1
9 inflammatory leiomyosarcoma 30.9 MYOG DES
10 heart sarcoma 30.9 MYOG MDM2
11 extraosseous osteosarcoma 30.9 MYOG MDM2 CDK4 CD68
12 neurofibroma 30.9 VIM MUC1 F13A1 ACTC1
13 epithelioid sarcoma 30.9 VIM MUC1 CD68
14 chordoma 30.8 VIM SERPINA3 PDGFRB MUC1 DES
15 sarcomatoid squamous cell skin carcinoma 30.8 SERPINA3 MYOG
16 myxoid liposarcoma 30.8 MDM2 HMGA2 DDIT3 CDK4
17 malignant granular cell myoblastoma 30.8 SERPINA3 CD68
18 histiocytosis 30.8 TNFRSF8 SERPINA3 PTPRC ALK
19 carcinosarcoma 30.7 VIM MUC1 DES ACTC1
20 connective tissue benign neoplasm 30.7 SERPINA3 PDGFRB MDM2 CDK4 CD68
21 malignant fibrous histiocytoma of bone 30.7 MYOD1 DES
22 desmoid tumor 30.7 PDGFRB DES ACTC1
23 granular cell tumor 30.7 VIM SERPINA3 DES CD68
24 ring chromosome 30.7 MDM2 HMGA2 CDK4
25 malignant giant cell tumor of soft parts 30.7 PTPRC CD68 ACTC1
26 myoepithelioma 30.7 VIM PTPRC MUC1 ACTC1
27 fibromatosis 30.7 VIM DES ACTC1
28 well-differentiated liposarcoma 30.7 MUC1 MDM2 HMGA2 DDIT3 CDK4
29 malignant histiocytosis 30.7 TNFRSF8 SERPINA3 SERPINA1
30 benign ependymoma 30.7 VIM MUC1 MDM2
31 neurilemmoma 30.6 VIM SERPINA3 PDGFRB MUC1 DES ACTC1
32 fibrous meningioma 30.6 VIM MUC1 F13A1
33 chondrosarcoma 30.6 VIM SERPINA3 MUC1 MDM2 CDK4
34 rare tumor 30.6 DES ACTC1
35 langerhans cell histiocytosis 30.6 PTPRC F13A1 CD68
36 cutaneous fibrous histiocytoma 30.6 VIM SERPINA3 F13A1 DES CD68 ACTC1
37 cellular myxoid liposarcoma 30.6 MDM2 DDIT3 CDK4
38 pleomorphic lipoma 30.6 SERPINA3 MDM2 HMGA2 CDK4
39 inflammatory mfh 30.6 SERPINA3 MDM2 CDK4 CD68
40 cystadenocarcinoma 30.6 VIM SERPINA3 PTPRC MUC1 ACTC1
41 lymphoma, hodgkin, classic 30.5 TNFRSF8 PTPRC CD68 ALK
42 epulis 30.5 VIM SERPINA3 DES CD68
43 mucinous adenocarcinoma 30.5 VIM MUC1 ALK
44 vascular cancer 30.5 SERPINA3 PDGFRB MYOG CD68
45 leiomyoma 30.5 VIM HMGA2 DES ACTC1
46 adenocarcinoma 30.4 PDGFRB MUC1 MDM2 CDK4 ALK
47 ectomesenchymoma 30.4 MYOG HMGA2 DES
48 angiosarcoma 30.4 VIM MYOG MUC1 MDM2 CD68
49 dedifferentiated liposarcoma 30.4 MYOG MDM2 HMGA2 DES DDIT3 CDK4
50 undifferentiated embryonal sarcoma of the liver 30.4 SERPINA3 MYOG MYOD1 MDM2 CDK4

Graphical network of the top 20 diseases related to Malignant Fibroxanthoma:



Diseases related to Malignant Fibroxanthoma

Symptoms & Phenotypes for Malignant Fibroxanthoma

GenomeRNAi Phenotypes related to Malignant Fibroxanthoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.55 ALK CDK4 MUC1 PDGFRB VIM
2 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.35 CDK4 MUC1 PDGFRB PTPRC VIM
3 Reduced mammosphere formation GR00396-S 9.17 CDK4 DDIT3 DES F13A1 MDM2 PTPRC

MGI Mouse Phenotypes related to Malignant Fibroxanthoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10 ACTC1 CDK4 DDIT3 DES F13A1 HSPB2
2 homeostasis/metabolism MP:0005376 9.97 ACTC1 ALK CDK4 DDIT3 DES EREG
3 muscle MP:0005369 9.56 ACTC1 CDK4 DES MDM2 MYOD1 MYOG
4 neoplasm MP:0002006 9.17 ALK CDK4 DDIT3 EREG MDM2 MYOD1

Drugs & Therapeutics for Malignant Fibroxanthoma

Drugs for Malignant Fibroxanthoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 104)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mechlorethamine Approved, Investigational Phase 2, Phase 3 51-75-2 4033
2
Ifosfamide Approved Phase 2, Phase 3 3778-73-2 3690
3
Epirubicin Approved Phase 3 56420-45-2 41867
4
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
5
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
6
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
7
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
8
Etoposide Approved Phase 3 33419-42-0 36462
9
Lenograstim Approved, Investigational Phase 3 135968-09-1
10
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
11
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
12
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
13
Isophosphamide mustard Phase 2, Phase 3 0
14 Etoposide phosphate Phase 3
15 Anti-Bacterial Agents Phase 2, Phase 3
16 Alkylating Agents Phase 2, Phase 3
17 Antibiotics, Antitubercular Phase 2, Phase 3
18 Topoisomerase Inhibitors Phase 2, Phase 3
19
Liposomal doxorubicin Phase 2, Phase 3 31703
20
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
21
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
22
Indinavir Approved Phase 2 150378-17-9 5362440
23
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
24
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
25
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
26
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
27
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
28
leucovorin Approved Phase 2 58-05-9 6006 143
29
Bevacizumab Approved, Investigational Phase 2 216974-75-3
30
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
31
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
32
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
33
Pembrolizumab Approved Phase 2 1374853-91-4
34
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
35
Vidarabine Approved, Investigational Phase 2 24356-66-9 32326 21704
36
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
37
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
38
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
39
nivolumab Approved Phase 2 946414-94-4
40
Ipilimumab Approved Phase 2 477202-00-9
41
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
42
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
43
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
44
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
45
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
46
Saracatinib Investigational Phase 2 379231-04-6
47 Exatecan Investigational Phase 2 171335-80-1
48
Camptothecin Experimental Phase 2 7689-03-4
49 Soblidotin Investigational Phase 2 149606-27-9
50
Emodepside Investigational, Vet_approved Phase 2 155030-63-0

Interventional clinical trials:

(show top 50) (show all 72)
# Name Status NCT ID Phase Drugs
1 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS) Unknown status NCT01344018 Phase 3
3 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
4 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
6 Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
7 A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcomas (RPS) Completed NCT00091351 Phase 3
8 Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
10 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
11 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
12 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Completed NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
13 TRUSTS: A Phase IIB/III Multicenter Study Comparing the Efficacy of TRabectedin Administered as a 3-Hour or 24-Hour Infusion to Doxorubicin in Patients With Advanced or Metastatic Untreated Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
14 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
15 Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
16 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
17 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
18 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate
19 Phase II Open-Label Study of Sunitinib Malate (SU011248) in Adult Patients With Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
20 A Phase 2 Study of Intravenous REOLYSIN® (Wild-Type Reovirus) in the Treatment of Patients With Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
21 A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas Completed NCT00245102 Phase 2 sorafenib tosylate
22 A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
23 A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas Completed NCT00112463 Phase 2 romidepsin
24 Phase I/II Trial of Torisel and Liposomal Doxorubicin in Patients With Advanced Soft Tissue and Bone Sarcomas Completed NCT00949325 Phase 1, Phase 2 temsirolimus plus liposomal doxorubicin
25 Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
26 A Study of Bevacizumab, a Humanized Monoclonal Antibody Against Vascular Endothelial Growth Factor (VEGF), in Combination With Chemotherapy for Treatment of Osteosarcoma Completed NCT00667342 Phase 2 Cisplatin;Doxorubicin;Methotrexate;Ifosfamide;etoposide
27 Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group Completed NCT00041236 Phase 2 exatecan mesylate
28 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
29 A Phase II Study of Intravenous TZT-1027, Administered Weekly Times Two, Every Three Weeks, to Patients With Advanced or Metastatic Soft Tissue Sarcomas (STS) With Prior Exposure to Anthracycline-Based Chemotherapy Completed NCT00064220 Phase 2 soblidotin
30 A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
31 Efficacy And Safety Study Of Brostallicin In Patients With Locally Advanced Or Metastatic Soft Tissue Sarcoma Failing One Prior Chemotherapy Treatment Completed NCT00041249 Phase 2 brostallicin
32 Phase II Study of Glivec (Imatinib) in Locally Advanced and/or Metastatic Soft Tissue Sarcomas Expressing the t(17;22)(q22;q13) Translocation Resulting in a COL1A1/PDGF-beta Fusion Protein i.e. DermatoFibroSarcoma Protuberans (DFSP) and Giant Cell Fibroblastoma (GCF) Completed NCT00085475 Phase 2 imatinib mesylate
33 Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI) Completed NCT00526149 Phase 2 BI 2536
34 Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
35 A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
36 A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin
37 SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity Recruiting NCT03092323 Phase 2 Pembrolizumab
38 A Phase 1b Single Center Investigation of Safety/Efficacy of Nivolumab (Opdivo®) and ABI-009 (Nab-rapamycin) in Patients With Advanced Undifferentiated Pleomorphic Sarcoma, Liposarcoma, Chondrosarcoma, Osteosarcoma and Ewing Sarcoma Recruiting NCT03190174 Phase 1, Phase 2 Nab-Rapamycin
39 Clinical Study to Assess Efficacy and Safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Recruiting NCT03449108 Phase 2 Cyclophosphamide;Fludarabine;Fludarabine Phosphate
40 A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma Recruiting NCT02923778 Phase 2
41 A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas Recruiting NCT03899805 Phase 2 Eribulin;Pembrolizumab
42 Phase II Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma Recruiting NCT03307616 Phase 2
43 Hypofractionated 5x5 Gy Radiotherapy With Sequential Doxorubicin and Ifosfamide-based Chemotherapy in Primary Unresectable or Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Recruiting NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
44 Preoperative Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Recruiting NCT03989596 Phase 2
45 A Phase I Study to Assess the Safety and Tolerability of Pembrolizumab in Combination With Fixed Rate Gemcitabine Chemotherapy in Patients With Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma Recruiting NCT03123276 Phase 1, Phase 2 Pembrolizumab;Gemcitabine
46 A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma Active, not recruiting NCT02601209 Phase 1, Phase 2 Pazopanib;Pazopanib Hydrochloride;Sapanisertib
47 A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination With Pazopanib for Refractory Soft Tissue Sarcoma Active, not recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
48 A Phase II Study of Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers Active, not recruiting NCT02392637 Phase 2 Abraxane (Nab-Paclitaxel);Cisplatin;Gemcitabine
49 Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma Active, not recruiting NCT02500797 Phase 2
50 Non-randomized Single-center Study Phase II Evaluating the Efficacy and Toxicity of Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Enrolling by invitation NCT01883518 Phase 1, Phase 2

Search NIH Clinical Center for Malignant Fibroxanthoma

Cochrane evidence based reviews: histiocytoma, malignant fibrous

Genetic Tests for Malignant Fibroxanthoma

Anatomical Context for Malignant Fibroxanthoma

MalaCards organs/tissues related to Malignant Fibroxanthoma:

40
Bone, Breast, Lung, Heart, Liver, Skin, Kidney

Publications for Malignant Fibroxanthoma

Articles related to Malignant Fibroxanthoma:

(show top 50) (show all 3712)
# Title Authors PMID Year
1
Transarterial catheter embolization of a sarcoma for preoperative conditioning. 54 61
20464676 2010
2
Analysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistance. 54 61
20368975 2010
3
Malignant fibrous histiocytoma--pleomorphic sarcoma, NOS gene expression, histology, and clinical course. A pilot study. 54 61
19159951 2010
4
Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer. 54 61
17229543 2007
5
High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors. 54 61
16740036 2006
6
[Malignant fibrous histiocytoma: pleomorphic sarcoma NOS or pleomorphic fibrosarcoma]. 54 61
15702318 2005
7
[Gastrointestinal stromal tumor: a clinicopathological study of 74 cases]. 54 61
15796874 2005
8
Histiocyte-like cells expressing factor XIIIa do not belong to the neoplastic cell population in malignant fibrous histiocytoma. 54 61
16047946 2005
9
Dermatofibrosarcoma protuberans--an update. 54 61
16279228 2004
10
Interleukin-6/soluble interleukin-6 receptor signaling attenuates proliferation and invasion, and induces morphological changes of a newly established pleomorphic malignant fibrous histiocytoma cell line. 54 61
15277221 2004
11
Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity. 54 61
15221942 2004
12
Expression of anaplastic lymphoma kinase in soft tissue tumors: an immunohistochemical and molecular study of 249 cases. 54 61
15188137 2004
13
Expression of betacellulin, heparin-binding epidermal growth factor and epiregulin in human malignant fibrous histiocytoma. 54 61
15274392 2004
14
The expression and prognostic significance of bone morphogenetic protein-2 in patients with malignant fibrous histiocytoma. 54 61
15174563 2004
15
The expression of selected immunocytochemical diagnostic markers in the case of chondrosarcoma with a mesenchymal component. 54 61
14655155 2003
16
Anaplastic lymphoma kinase negative sarcomatoid variant of anaplastic large-cell lymphoma presenting as a malignant fibrous histiocytoma. 54 61
12799899 2003
17
Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. 54 61
12640106 2003
18
Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years. 54 61
12181274 2002
19
Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. 54 61
11688574 2001
20
Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. 54 61
11555609 2001
21
Connective tissue growth factor expression in pediatric myofibroblastic tumors. 54 61
11200489 2001
22
Primary cardiac malignant fibrous histiocytoma in the right ventricular infundibulum treated with a cavo-pulmonary shunt and coronary embolization. 54 61
11194295 2000
23
Locus-specific multifluor FISH analysis allows physical characterization of complex chromosome abnormalities in neoplasia. 54 61
10862042 2000
24
Analysis of p53 and mdm2 proteins in malignant fibrous histiocytoma in absence of gene alteration: prognostic significance. 54 61
10628802 1999
25
Factor XIIIa-immunoreactivity in tumors of the central nervous system. 54 61
9561329 1998
26
Differential expression of connective tissue growth factor gene in cutaneous fibrohistiocytic and vascular tumors. 54 61
9550312 1998
27
Immunohistochemical status of p53, mdm2 and Ki-67 in malignant fibrous histiocytoma. 54 61
9640970 1998
28
MDM2 amplification, P53 mutation, and accumulation of the P53 gene product in malignant fibrous histiocytoma. 54 61
8919547 1996
29
[Pulmonary malignant fibrous histiocytoma treated with cisplatin plus etoposide followed by surgery]. 54 61
8538096 1995
30
Prognostic relevance of Ki-67 antigen and c-myc oncoprotein in malignant fibrous histocytoma. 54 61
8572578 1995
31
Prognostic implication of the p53 protein and Ki-67 antigen immunohistochemistry in malignant fibrous histiocytoma. 54 61
8625155 1995
32
Enhanced expression of catalytic subunit isoform PP1 gamma 1 of protein phosphatase type 1 in malignant fibrous histiocytoma. 54 61
7850251 1994
33
Malignant fibrous histiocytoma in chordoma--immunohistochemical evidence of transformation from chordoma to malignant fibrous histiocytoma. 54 61
8091802 1994
34
Hsp27 expression in neuroblastoma: correlation with disease stage. 54 61
8169976 1994
35
No rearrangements of the CHOP gene in malignant fibrous histiocytoma. 54 61
8143276 1994
36
Prognostic influence of HSP-27 expression in malignant fibrous histiocytoma: a clinicopathological and immunohistochemical study. 54 61
1313743 1992
37
Platelet-derived growth factor receptor (beta-subunit) immunoreactivity in soft tissue tumors. 54 61
1309926 1992
38
Evaluation of CD68 and other histiocytic antigens in angiomatoid malignant fibrous histiocytoma. 54 61
1676879 1991
39
Cell marker studies in undifferentiated soft tissue sarcoma. 54 61
1752649 1991
40
Congenital, infiltrating giant-cell angioblastoma. A new entity? 54 61
1989466 1991
41
Comparative immunohistochemistry of malignant fibrous histiocytoma and sarcomatoid carcinoma of the urinary tract. 54 61
1851349 1991
42
Myogenic regulatory protein (MyoD1) expression in childhood solid tumors: diagnostic utility in rhabdomyosarcoma. 54 61
2260621 1990
43
Immunohistochemical study of 4-hydroxyaminoquinoline 1-oxide-induced rat malignant fibrous histiocytoma. 54 61
2158461 1990
44
Pleomorphic malignant fibrous histiocytoma in bladder diverticulum. 61
31788429 2020
45
The Management of Head and Neck Sarcoma. 61
31934973 2020
46
Malignant fibrous neoplasms of long bones: analysis of the surveillance, epidemiology, and end results database from 1973 to 2015. 61
31969161 2020
47
Primary undifferentiated pleomorphic sarcoma (Malignant fibrous histiocytoma) of the lung: A case report. 61
31998481 2020
48
Uterine pleomorphic leiomyosarcoma with osteoclastic giant cells: Case report with peritoneal washing cytology and cell block study. 61
31932012 2020
49
A population-based study of soft tissue sarcoma incidence and survival in Australia: An analysis of 26,970 cases. 61
31520939 2019
50
Malignant fibrous histiocytoma amplified sequence 1 alleviates inflammation and renal fibrosis in diabetic nephropathy by inhibiting TLR4. 61
31696221 2019

Variations for Malignant Fibroxanthoma

Copy number variations for Malignant Fibroxanthoma from CNVD:

7 (show all 41)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 18958 1 148000000 153300000 Gain Malignant fibrous histiocytomas
2 27753 1 212100000 222100000 Loss Malignant fibrous histiocytomas
3 33593 1 46500000 56200000 Gain Malignant fibrous histiocytomas
4 35188 1 60900000 69500000 Gain Malignant fibrous histiocytomas
5 37769 1 94500000 99400000 Gain Malignant fibrous histiocytomas
6 39415 10 114900000 121700000 Loss Malignant fibrous histiocytomas
7 50207 11 115400000 134452384 Loss Malignant fibrous histiocytomas
8 59633 11 76700000 85300000 Loss Malignant fibrous histiocytomas
9 60562 11 87900000 96700000 Loss Malignant fibrous histiocytomas
10 69083 12 5300000 14800000 Gain Malignant fibrous histiocytomas
11 76673 13 34700000 48900000 Loss Malignant fibrous histiocytomas
12 78011 13 48900000 57600000 Loss Malignant fibrous histiocytomas
13 86677 14 64000000 88900000 Gain Malignant fibrous histiocytomas
14 88587 14 92800000 106368585 Gain Malignant fibrous histiocytomas
15 101715 16 45500000 54500000 Loss Malignant fibrous histiocytomas
16 103579 16 6300000 10300000 Loss Malignant fibrous histiocytomas
17 107007 17 11200000 15900000 Gain Malignant fibrous histiocytomas
18 107027 17 11200000 22100000 Gain Malignant fibrous histiocytomas
19 107535 17 15900000 22100000 Gain Malignant fibrous histiocytomas
20 112060 17 37800000 44800000 Gain Malignant fibrous histiocytomas
21 119810 18 17300000 23300000 Gain Malignant fibrous histiocytomas
22 122735 18 59800000 76117153 Loss Malignant fibrous histiocytomas
23 127802 19 37100000 47800000 Gain Malignant fibrous histiocytomas
24 134297 2 1 12800000 Loss Malignant fibrous histiocytomas
25 142547 2 225800000 237000000 Loss Malignant fibrous histiocytomas
26 154853 20 49200000 54400000 Gain Malignant fibrous histiocytomas
27 163375 22 27900000 35900000 Gain Malignant fibrous histiocytomas
28 163745 22 30500000 39300000 Gain Malignant fibrous histiocytomas
29 164763 22 39300000 49691432 Loss Malignant fibrous histiocytomas
30 178974 3 83700000 89400000 Gain Malignant fibrous histiocytomas
31 187572 4 52400000 59200000 Gain Malignant fibrous histiocytomas
32 192956 5 121500000 143100000 Loss Malignant fibrous histiocytomas
33 198017 5 18500000 23300000 Gain Malignant fibrous histiocytomas
34 214607 6 63500000 75900000 Gain Malignant fibrous histiocytomas
35 221899 7 147500000 158821424 Loss Malignant fibrous histiocytomas
36 225328 7 4500000 7200000 Gain Malignant fibrous histiocytomas
37 226671 7 61100000 71800000 Gain Malignant fibrous histiocytomas
38 237234 8 2200000 19100000 Loss Malignant fibrous histiocytomas
39 244141 8 93500000 99100000 Gain Malignant fibrous histiocytomas
40 250775 9 2200000 9000000 Loss Malignant fibrous histiocytomas
41 255895 9 86100000 113900000 Gain Malignant fibrous histiocytomas

Expression for Malignant Fibroxanthoma

Search GEO for disease gene expression data for Malignant Fibroxanthoma.

Pathways for Malignant Fibroxanthoma

Pathways related to Malignant Fibroxanthoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.29 VIM TNFRSF8 SERPINA3 SERPINA1 PTPRC PDGFRB
2 10.66 VIM DES ACTC1

GO Terms for Malignant Fibroxanthoma

Cellular components related to Malignant Fibroxanthoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.61 VIM TNFRSF8 SERPINA3 SERPINA1 PTPRC MUC1
2 platelet alpha granule lumen GO:0031093 9.33 SERPINA3 SERPINA1 F13A1
3 protein-DNA complex GO:0032993 8.8 MYOG HMGA2 DDIT3

Biological processes related to Malignant Fibroxanthoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of gene expression GO:0010468 9.62 PTPRC MYOD1 MDM2 CDK4
2 myotube differentiation GO:0014902 9.4 MYOG MYOD1
3 positive regulation of stem cell proliferation GO:2000648 9.37 PTPRC HMGA2
4 positive regulation of skeletal muscle fiber development GO:0048743 9.26 MYOG MYOD1
5 muscle cell fate commitment GO:0042693 9.16 MYOG MYOD1
6 positive regulation of fibroblast proliferation GO:0048146 9.13 PDGFRB EREG CDK4
7 muscle filament sliding GO:0030049 8.8 VIM DES ACTC1

Molecular functions related to Malignant Fibroxanthoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.02 MYOG MYOD1 MUC1 HMGA2 DDIT3

Sources for Malignant Fibroxanthoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....